（股份代號：1276） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年12月10日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：2025-197 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年12月10日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-1 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年12月10日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-1 ...

Core Insights - The article highlights the top and bottom AH share premium rates, with Northeast Electric (00042) leading at 881.82% and Ningde Times (03750) at -8.10% [1][2][3] Group 1: Top AH Share Premium Rates - Northeast Electric (00042) has a premium rate of 881.82% with H-share at 0.275 HKD and A-share at 2.25 CNY [1] - Zhejiang Shibao (01057) follows with a premium rate of 269.35%, H-share at 3.980 HKD and A-share at 12.27 CNY [1] - Hongye Futures (03678) ranks third with a premium rate of 265.32%, H-share at 3.460 HKD and A-share at 10.55 CNY [1] Group 2: Bottom AH Share Premium Rates - Ningde Times (03750) has the lowest premium rate at -8.10%, with H-share at 498.400 HKD and A-share at 382.38 CNY [1] - China Merchants Bank (03968) has a premium rate of 0.67%, H-share at 50.400 HKD and A-share at 42.36 CNY [1] - Heng Rui Pharmaceutical (01276) follows closely with a premium rate of 1.02%, H-share at 75.150 HKD and A-share at 63.38 CNY [1] Group 3: Top and Bottom Deviation Values - The highest deviation values are led by Beijing Jingcheng Machinery Electric Company (00187) at 26.20%, followed by Guanghetong (00638) at 23.44% and Chenming Paper (01812) at 23.09% [1][2] - Conversely, the lowest deviation values are recorded by GAC Group (02238) at -19.94%, Jiangsu Ninghu Expressway (00177) at -15.21%, and Shenzhen Expressway (00548) at -12.71% [1][3]

Core Insights - The report from CMB International indicates a leading rating for the mainland pharmaceutical industry, following the National Healthcare Security Administration's announcement of the results from the 2025 Innovative Drug High-Quality Development Conference [1] Group 1: Industry Developments - The recent negotiations for the medical insurance and commercial insurance innovative drug catalog have resulted in many innovative pharmaceutical companies covered by CMB International having products newly included or successfully renewed in the insurance coverage [1] - Companies such as Heng Rui Medicine (600276), Innovent Biologics (01801), CanSino Biologics (09926), and China National Pharmaceutical Group (01177) have more than five products that received new coverage or new indications [1] Group 2: Market Outlook - The inclusion of more new drugs in the catalog is expected to enhance clinical medication levels and improve the overall R&D return rates in the innovative drug industry [1] - The introduction of commercial insurance funds is anticipated to provide significant incremental funding for innovative drug payments, paving the way for a diversified payment system alongside basic medical insurance [1] Group 3: Future Growth Potential - CMB International is optimistic about the sales growth potential of newly included products/indications in 2026, particularly for potential blockbuster products from companies like CanSino Biologics [1] - The report emphasizes the importance of monitoring the actual execution and payment situations of the first batch of commercial insurance catalog, as well as the dynamic adjustments in the list and pricing, and the long-term development opportunities arising from real-world data accumulation [1]

Core Insights - The article highlights the top and bottom AH share premium rates as of December 9, with Northeast Electric (00042) leading at a premium of 938.46% and Ningde Times (03750) at the bottom with a premium of -6.40% [1][2] Group 1: Top AH Share Premium Rates - Northeast Electric (00042) has a premium rate of 938.46% and a deviation value of 69.76% [1][2] - Beijing Jingcheng Machinery Electric (00187) follows with a premium of 271.15% and a deviation value of 38.89% [1][2] - Hongye Futures (03678) ranks third with a premium of 270.18% and a deviation value of 3.33% [1][2] Group 2: Bottom AH Share Premium Rates - Ningde Times (03750) has a premium rate of -6.40% and a deviation value of 3.51% [1][2] - China Merchants Bank (03968) shows a premium of -0.87% with a deviation value of -0.30% [1][2] - Heng Rui Medicine (01276) has a premium of 1.70% and a deviation value of -1.61% [1][2] Group 3: Deviation Values - The highest deviation values are seen in Northeast Electric (00042) at 69.76%, Beijing Jingcheng Machinery Electric (00187) at 38.89%, and China Metallurgical Group (01618) at 31.96% [1][2] - The lowest deviation values are recorded for GAC Group (02238) at -19.60%, Jiangsu Ninghu Expressway (00177) at -16.52%, and Shenzhen Expressway (00548) at -13.03% [1][2]

Group 1 - The article highlights the top three and bottom three AH premium rates for stocks as of December 8, with Northeast Electric (00042) leading at 900.00% [1] - The second and third highest AH premium rates are for Hongye Futures (03678) at 271.02% and Zhejiang Shibao (01057) at 263.14% [1] - The lowest AH premium rates are for Ningde Times (03750) at -7.18%, followed by China Merchants Bank (03968) at 0.50% and Hengrui Medicine (01276) at 3.12% [1] Group 2 - The article provides a detailed ranking of the top ten AH stocks by premium rate, with Northeast Electric (00042) having a significant premium of 900.00% and a deviation value of 33.05% [1] - Other notable stocks in the top ten include Sinopec Oilfield Service (01033) with a premium of 259.21% and a deviation value of -5.20% [1] - The bottom ten AH stocks by premium rate include Weichai Power (02338) with a premium of 5.92% and a deviation value of -3.57% [1] Group 3 - The article also lists the top ten AH stocks by deviation value, with Northeast Electric (00042) again leading with a deviation of 33.05% [1] - Guanghetong (00638) and Beijing Jingcheng Machinery (00187) follow with deviation values of 28.42% and 26.94% respectively [1] - The bottom three stocks by deviation value include GAC Group (02238) at -17.56%, Jiangsu Ninghu Expressway (00177) at -17.19%, and Shenzhen Expressway (00548) at -11.56% [1]

Summary of Hengrui Medicine (600276.SS) R&D Day Takeaway Company Overview - **Company**: Hengrui Medicine (600276.SS) - **Industry**: Pharmaceuticals, specifically focusing on oncology, metabolism, and respiratory treatments Key Points Pipeline Strategy - Hengrui aims to develop **best-in-disease treatments** by leveraging its resources as a large pharmaceutical company [4] - The oncology pipeline includes: - A **one-stop solution** for breast cancer treatment covering various subgroups with drugs like HER2 TKI, HER2 ADC, CDK4/6i, SERD, and PARPi [4] - Enrollment of **95,000+ patients** in clinical trials for adjuvant therapy across six cancer indications [4] - Research on **10+ indications** for SHR-A1811 (HER2 ADC) and SHR-A2101 (Nectin-4 ADC) in phase 1 [4] - Development of **precision treatments** for pancreatic cancer targeting mutations such as KRAS and MTAP [4] Metabolism Portfolio - Hengrui is addressing obesity with a comprehensive solution that includes: - **HRS-9531** (GLP-1/GIP injection) with a filed NDA, targeting patients with BMI 35+ [4] - **HRS-9531 oral peptide** in phase 2, aiming for better tolerability [4] - **HRS-7535** (oral GLP-1 small molecule) in development as a cost-effective option [4] - **HRS-4729** (GLP-1/GIP/GCGR injection) in phase 1, focusing on weight loss and liver fat reduction [4] Respiratory Pipeline - Hengrui has established a pipeline for respiratory diseases, including: - **SHR-1905** (twice-yearly TSLP mAb) in phase 3 for type 1 and type 2 inflammation [5] - **HRS-9821** (PDE3/4i) in phase 1, offering convenient powder inhalation [5] Global Expansion Strategy - Hengrui is pursuing a **collaboration strategy** for global expansion while building its clinical operation capabilities [6] - Significant progress noted in the **NewCo Kailera** for the GLP-1 portfolio, including: - Completion of phase 1 bridging study for HRS-9531 in Australia and plans for a phase 3 global trial by the end of 2025 [6] - Establishment of a leadership team and hiring of over **150 employees** for operations [6] - Raising **US$600 million** to fund the global phase 3 trial and portfolio expansion [6] Financial Outlook - **Price Target**: Rmb76.11 with a current price of Rmb61.62, indicating an upside of **23.5%** [8] - **Market Cap**: Rmb393.1 billion / $55.6 billion [8] - **Revenue Forecast**: Expected to grow from Rmb27,984.6 million in 2024 to Rmb41,883.6 million by 2027 [8] - **Key Risks**: - Slower ramp-up of innovative drugs post NRDL listing [6] - Potential failure in key late-stage R&D programs [6] - Higher-than-expected R&D and administrative expenses for global expansion [6] - Greater-than-expected price cuts for generics and innovative drugs [6] Technological Advancements - Continuous upgrading of technology platforms, including: - Development of **RIPTAC** for addressing drug resistance [7] - Enhancements in **siRNA** and peptide platforms for better patient compliance [7] - Exploration of innovative linkers and payloads for targeted delivery [7] Conclusion Hengrui Medicine is strategically positioned in the pharmaceutical industry with a robust pipeline across oncology, metabolism, and respiratory treatments. The company's focus on global expansion through collaborations and technological advancements presents significant growth potential, albeit with inherent risks associated with R&D and market dynamics.

恒瑞医药 20251205 摘要 恒瑞医药坚持创新和国际化双轮驱动战略，聚焦肿瘤、代谢、心血管、 自免及退行性疾病等领域，通过技术创新和"借船出海"策略拓展国际 市场，自 2023 年以来已达成 12 笔对外许可交易，总金额近 280 亿美 元。 公司通过建立和迭代细胞治疗、核酸药物、基因治疗及蛋白降解剂等新 兴技术平台，并注重创新模块的基本功，组合成差异化的治疗方案，例 如在代谢领域开发 PCSK9 抑制剂和长效小分子疗法。 恒瑞医药在肿瘤治疗领域构建四位一体的协同创新疗法，包括免疫治疗 （PD-1、细胞因子、细胞治疗）、靶向化疗（ADC、多肽-核素连接）、 支持治疗和精准治疗（KRAS 抑制剂），并探索融合不同技术平台以实 现更高效的肿瘤免疫反应。 在代谢疾病领域，恒瑞已有多个糖尿病口服产品上市，并计划于 2026 年推出减重药 9,531，该产品临床数据显示出良好的疗效和安全性，公 司正致力于解决现有减重药的副作用和依从性问题，并研究新型给药方 式。 Q&A 恒瑞医药未来的发展战略是什么？ 恒瑞医药近年来在研发投入和国际化方面取得了哪些成就？ 截至目前，恒瑞医药累计投入研发费用已超过 500 亿人民币， ...

Core Viewpoint - The recent adjustments to the national basic medical insurance directory and the introduction of the commercial insurance innovative drug directory mark significant steps towards enhancing access to innovative treatments in China, particularly for high-cost therapies like CAR-T drugs [2][6]. Summary by Sections National Basic Medical Insurance Directory Adjustments - A total of 114 new drugs were added to the basic medical insurance directory, including 50 first-class innovative drugs [2]. - The total number of drugs in the basic medical insurance directory has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [3]. - New inclusions cover various fields such as oncology, chronic diseases, mental health, and pediatric medications, with several rare disease treatments also added [3]. Commercial Insurance Innovative Drug Directory - The commercial insurance innovative drug directory aims to include high-innovation drugs that exceed the basic insurance scope but offer significant clinical value and patient benefits [6]. - A total of 121 drugs underwent formal review for the commercial insurance directory, with 24 entering price negotiation, ultimately resulting in 19 drugs from 18 companies being included [6]. - Notable inclusions are five CAR-T therapies, which previously cost over one million yuan per injection, making them unaffordable for many patients [6]. Performance of Pharmaceutical Companies - Several leading pharmaceutical companies have reported their successes in the 2025 national medical insurance negotiations, with Heng Rui Pharmaceutical having 20 drugs included, contributing 7.554 billion yuan to their total revenue [5]. - Innovent Biologics announced that 7 of its new drugs were included in the updated national medical insurance directory, with 12 of its 17 innovative drugs now covered [5]. Specific Drug Inclusions - The directory includes drugs for Alzheimer's disease, such as the monoclonal antibodies from Eisai and Eli Lilly, and several rare disease treatments [7]. - Some high-profile drugs, like Novo Nordisk's semaglutide and Bristol-Myers Squibb's nivolumab, were not included despite passing the formal review [8]. Implementation Timeline - The new directory is set to be officially implemented nationwide on January 1, 2026 [9].